The estimated Net Worth of Vimal Kavuru is at least $2.76 Milhão dollars as of 25 September 2023. Vimal Kavuru owns over 676,371 units of Acasti Pharma Inc stock worth over $2,756,336 and over the last 3 years Vimal sold ACST stock worth over $0.
Sign up
Vimal Kavuru ACST stock SEC Form 4 insiders trading
Vimal has made over 1 trades of the Acasti Pharma Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Vimal bought 676,371 units of ACST stock worth $1,251,286 on 25 September 2023.
The largest trade Vimal's ever made was buying 676,371 units of Acasti Pharma Inc stock on 25 September 2023 worth over $1,251,286. On average, Vimal trades about 135,274 units every 0 days since 2021. As of 25 September 2023 Vimal still owns at least 1,188,076 units of Acasti Pharma Inc stock.
You can see the complete history of Vimal Kavuru stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Vimal Kavuru's mailing address?
Vimal's mailing address filed with the SEC is 103 CARNEGIE CENTER, SUITE 300, PRINCETON, NJ, 08540.
Insiders trading at Acasti Pharma Inc
Over the last 3 years, insiders at Acasti Pharma Inc have traded over $0 worth of Acasti Pharma Inc stock and bought 676,752 units worth $1,252,067 . The most active insiders traders include Vimal Kavuru, John Canan, eR. Loch Macdonald. On average, Acasti Pharma Inc executives and independent directors trade stock every 13 days with the average trade being worth of $785,032. The most recent stock trade was executed by Vimal Kavuru on 25 September 2023, trading 676,371 units of ACST stock currently worth $1,251,286.
What does Acasti Pharma Inc do?
acasti pharma, inc., a subsiduary of neptune technologies & bioressources, is a quebec-based biopharmaceutical dedicated in advancing a proprietary portfolio based on marine phospholipids. our products can be used in prescription, medical food and over-the-counter applications, either as a stand-alone, or, as a fixed-dose combination to exisitng productrs, for the prevention and treatment of cardiometabolic disorders.
What does Acasti Pharma Inc's logo look like?
Complete history of Vimal Kavuru stock trades at Acasti Pharma Inc
Acasti Pharma Inc executives and stock owners
Acasti Pharma Inc executives and other stock owners filed with the SEC include:
-
Janelle D' Alvise,
Pres, CEO, Corp. Sec. & Director -
Janelle D'Alvise,
Pres, CEO, Corp. Sec. & Director -
Brian D. Ford CPA, CA,
Chief Financial Officer -
Dr. Pierre Lemieux,
Co-Founder, COO & Chief Scientific Officer -
Dr. Pierre Lemieux M.D., Ph.D.,
Co-Founder, COO & Chief Scientific Officer -
Pierre Lemieux,
Chief Operating Officer -
Donald Olds,
Independent Director -
Jean-Marie Canan,
Director -
Jean-Daniel Belanger,
Secretary, Director- Corporate Affairs -
Brian Groch,
Chief Commercial Officer -
Laurent Harvey,
Vice President- Clinical and Non-Clinical Affairs -
Brian Ford,
Chief Financial Officer -
Janelle D'Alvise,
President, Chief Executive Officer, Director -
Roderick Carter,
Executive Chairman of the Board -
Prashant Kohli,
VP of Commercial Operations -
Dr. George Kottayil,
Chief Operating Officer of US -
Dr. Yves Lachance Ph.D.,
VP of Quality & Compliance -
Amresh Kumar,
VP Clinical Operations -
R. Loch Macdonald,
Chief Medical Officer -
Robert J Del Aversano,
Principal Financial Officer -
Michael Derby,
Director -
William A Haseltine,
Director -
John Canan,
Director -
Prashant Kohli,
Chief Executive Officer -
Vimal Kavuru,
-
A Brian Davis,
-
George Kottayil,
-
Edward Neugeboren,